Mizuho Securities USA LLC Sells 7,396 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mizuho Securities USA LLC decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 15.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,062 shares of the medical research company's stock after selling 7,396 shares during the period. Mizuho Securities USA LLC's holdings in Edwards Lifesciences were worth $2,578,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. LRI Investments LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $67,000. Lazard Asset Management LLC increased its holdings in shares of Edwards Lifesciences by 89.6% during the 1st quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company's stock worth $8,946,000 after purchasing an additional 44,257 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company's stock worth $622,695,000 after purchasing an additional 2,390,137 shares during the period. Bellevue Group AG increased its holdings in shares of Edwards Lifesciences by 8.3% during the 1st quarter. Bellevue Group AG now owns 1,103,136 shares of the medical research company's stock worth $105,416,000 after purchasing an additional 84,138 shares during the period. Finally, Kennedy Capital Management LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $2,440,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 over the last ninety days. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.10 during trading hours on Friday, reaching $70.48. 2,711,639 shares of the company were exchanged, compared to its average volume of 5,390,755. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock's fifty day moving average is $67.70 and its two-hundred day moving average is $75.73. The company has a market cap of $41.57 billion, a price-to-earnings ratio of 10.17, a P/E/G ratio of 3.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business earned $0.59 earnings per share. Edwards Lifesciences's quarterly revenue was up 8.9% on a year-over-year basis. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Daiwa America cut shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group lowered their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a "hold" rating on the stock in a research note on Friday, October 25th. Truist Financial lowered their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a "hold" rating on the stock in a research note on Friday, October 25th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a "neutral" rating to an "outperform" rating in a research note on Wednesday, July 31st. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 28th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.